TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9926031
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy
Study: 22616853
Drug: Placebo drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug treatment
Study: 116373
Drug: Cefaclor 2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 2, 3, or 4 g with or without 1 g probenecid, administered as single daily doses for three days
Study: 116373
Drug: Cefaclor 3
Normalized name: cefaclor 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 3 or 4 g
Study: 22288893
Drug: Dronabinol (DRO)
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dronabinol (DRO) 2.5 mg twice per day for 2 days
Study: 22288893
Drug: Dronabinol (DRO)
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dronabinol (DRO) 5 mg twice per day for 2 days
Study: 22288893
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) twice per day for 2 days
Study: 17394959
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate plus N-acetylcysteine (N-AC) infusion started just before contrast injection and continued for 12 h after PCI
Study: 17394959
Drug: Standard hydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hydration protocol consisting of intravenous isotonic saline for 12 h after PCI
Study: 1636805
Drug: Acute plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute plus maintenance treatment with imipramine (18 months)
Study: 6394778
Drug: 45% BCAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45% BCAA enriched (low leucine) amino acid solution
Study: 6394778
Drug: 25% BCAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% BCAA amino acid solution
Study: 6394778
Drug: 45% BCAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45% BCAA enriched (high leucine) amino acid solution
Study: 22856593
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg by mouth twice a day for 7 days)
Study: 9736552
Drug: Stavudine (d4T)
Normalized name: STAVUDINE (d4T)
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stavudine (d4T) 70 mg in fasting state
Study: 9736552
Drug: Stavudine (d4T)
Normalized name: STAVUDINE (d4T)
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stavudine (d4T) 70 mg 1 hour before a meal
Study: 9736552
Drug: Stavudine (d4T)
Normalized name: STAVUDINE (d4T)
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stavudine (d4T) 70 mg 5 minutes after a high-fat breakfast
Study: 26909845
Drug: Grape intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape intake of 50 g/day
Study: 21766228
Drug: GTP (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTP (500 mg GTP/day)
Study: 17275908
Drug: Intravitreal 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal 10% C3F8 infusion at the end of surgery
Study: 10681809
Drug: Lentinan treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentinan treatment for 2 months
Study: 7655202
Drug: Heparin sodium
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin sodium (+H)
Study: 7655202
Drug: No heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No heparin (-H)
Study: 9963
Drug: N-desmethyldiazepam (nordiazepam)
Normalized name: N-ethylurea
DrugBank: Nordazepam (DB14028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-desmethyldiazepam (nordiazepam) 5 mg
Study: 31094793
Drug: Low volume/high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low volume/high concentration (LVHC) - 0.1 mL·kg of 0.4% levobupivacaine
Study: 31094793
Drug: High volume/low
Approvals — FDA: no, EMA: no, PMDA: no
Description: High volume/low concentration (HVLC) - 0.2 mL·kg of 0.2% levobupivacaine
Study: 18575077
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg/day
Study: 15683500
Drug: Carvedilol 25
Normalized name: carvedilol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 25 mg/day
Study: 18635707
Drug: Immediate-release d-amphetamine
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release d-amphetamine sulphate 20 mg
Study: 11435337
Drug: Beta-blocker atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beta-blocker atenolol (100 mg once a day)
Study: 8117122
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (initial static Crs >= 1.8 ml/cm H2O/m)
Study: 31111882
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal treatment (Control Group)
Study: 31111882
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (TGs)
Study: 28035541
Drug: EAA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EAA plus leflflunomide and methotrexate (30 g/d)
Study: 21667450
Drug: Long-term psychoanalytic
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term psychoanalytic treatment
Study: 19304891
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg bevirimat solution delivered to the proximal small bowel via Enterion capsule
Study: 19304891
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg bevirimat solution delivered to the distal small bowel via Enterion capsule
Study: 8698959
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy focusing on interpersonal and developmental vulnerabilities
Study: 8698959
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy with a developmental focus
Study: 154426
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg b.i.d.)
Study: 2744064
Drug: temazepam 20
Normalized name: temazepam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: temazepam 20 mg
Study: 16923101
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg parecoxib
Study: 20427369
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g acetaminophen
Study: 20427369
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg parecoxib plus 5 g acetaminophen
Study: 10210023
Drug: Felbamate (FBM)
Normalized name: Felbamate
DrugBank: Felbamate (DB00949)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felbamate (FBM) in combination with Valproic Acid (VPA)
Study: 1877476
Drug: Intravenous urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous urokinase plus heparin
Study: 14564321
Drug: Heparin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin alone
Study: 6311782
Drug: mezlocillin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: mezlocillin (4 g iv 6‐hourly) plus cefotaxime (2 g iv 8‐hourly)
Study: 17627725
Drug: Sildenafil (Viagra),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (Viagra), up to one study tablet per day for 6 months
Study: 2891224
Drug: ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranitidine 150 mg bid
Study: 6108729
Drug: Temazepam 30
Normalized name: temazepam 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam 30 mg
Study: 27921320
Drug: Amiselimod 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiselimod 0.4 mg
Study: 29570538
Drug: Reboxetine (REB)
Normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (REB) 8 mg
Study: 21624418
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of CPG 7909 alone
Study: 21624418
Drug: BioThrax plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BioThrax plus 1 mg of CPG 7909
Study: 12577250
Drug: Subcutaneous amifostine
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous amifostine
Study: 8160899
Drug: Gentamicin/Clindamycin (G/C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin/Clindamycin (G/C)
Study: 21118743
Drug: Armodafinil 200
Normalized name: armodafinil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil 200 mg single dose
Study: 21118743
Drug: Modafinil 200
Normalized name: modafinil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 200 mg single dose
Study: 21118743
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily armodafinil 200 mg doses
Study: 10847311
Drug: No experimental
Approvals — FDA: no, EMA: no, PMDA: no
Description: No experimental treatment (control)
Study: 8635429
Drug: Antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drugs (AEDs) including carbamazepine (CBZ), phenytoin (PHT), phenobarbital (PB), valproate (VPA)
Study: 15847747
Drug: Antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drugs (AEDs)
Study: 3904437
Drug: Isoxicam 200
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoxicam 200 mg per day
Study: 3904437
Drug: Isoxicam dosages
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoxicam dosages ranging from 200 to 600 mg per day
Study: 26670665
Drug: Tibolone (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (1.25 mg/day for 24 weeks)
Study: 26670665
Drug: Control (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (without hormone replacement therapy)
Study: 20822038
Drug: Fentanyl pectin
Normalized name: Pectin
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl pectin nasal spray (FPNS)
Study: 16270403
Drug: Lamivudine only
Normalized name: Lamivudine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine only (100 mg daily)
Study: 27914653
Drug: Warfarin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin therapy (target INR of 2.0 to 3.0)
Study: 27914653
Drug: Aspirin 150mg
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 150mg daily
Study: 3897558
Drug: Oltipraz 15
Normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz 15 mg/kg
Study: 3897558
Drug: Oltipraz 25
Normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz 25 mg/kg
Study: 3897558
Drug: Divided dose
Normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided dose taken 6 hours apart
Study: 30781461
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no PRP injection)
Study: 16104039
Drug: Control regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control regimen (Day 1: OND 8 mg and DEX 20 mg before chemotherapy and OND 8 mg 8 hrs later; Days 2-3: OND 8 mg twice per day)
Study: 12115238
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 0.15 mg/kg/week (increased to 0.25 mg/kg/week, max 15 mg)
Study: 31882409
Drug: Once-weekly exenatide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly exenatide therapy
Study: 30777794
Drug: TP (thalidomide
Approvals — FDA: no, EMA: no, PMDA: no
Description: TP (thalidomide 100 mg/d for ≤12 months/until disease progression; prednisolone 50 mg on alternate days indefinitely/until disease progression; n=100)
Study: 30777794
Drug: VTP (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: VTP (subcutaneous bortezomib 1.3 mg/m2 every 2 weeks for 32 weeks, plus TP; n=103)
Study: 11978956
Drug: Metoprolol sustained-release
Normalized name: metoprolol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol sustained-release treatment
Study: 2275356
Drug: Oral metyrapone
Normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metyrapone tartrate
Study: 29149958
Drug: Immediate-release tacrolimus
Normalized name: tacrolimus Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release tacrolimus
Study: 18558914
Drug: Coordinated care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coordinated care plan including treatment for depression and anxiety disorders, containment strategy for somatisation, and service coordinator-assisted self-management.
Study: 14750201
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (Control group)
Study: 12524411
Drug: 0.4% GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% GTN ointment
Study: 2014460
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 0.45 mg/kg
Study: 2014460
Drug: Intramuscular midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular midazolam 0.15 mg/kg
Study: 2014460
Drug: Oral trimeprazine
Normalized name: trimeprazine
DrugBank: Alimemazine (DB01246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral trimeprazine tartrate 2 mg/kg, methadone 0.1 mg/kg, droperidol 0.15 mg/kg (TMD)
Study: 22838970
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors
Study: 7887119
Drug: Clonidine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (4 micrograms.kg‐1 loading dose in 30 min, maintained with 1 microgram.kg‐1.h‐1 infusion)
Study: 7887119
Drug: Labetalol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (0.2 mg.kg‐1 loading dose followed by 0.1 mg.kg‐1.h‐1 infusion)
Study: 3369996
Drug: Capsule intact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule intact group
Study: 30339244
Drug: 50% reduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% reduced individualized GH dose (GHRID; n = 27; 20 boys)
Study: 30339244
Drug: Unchanged individualized
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unchanged individualized GH dose (GHUID; n = 38; 27 boys)
Study: 30339244
Drug: Standard weight-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard weight-based dose (GHFIX; n = 33; 25 boys)
Study: 26192975
Drug: Creatine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (1 g/d)
Study: 22108476
Drug: Meriva (curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meriva (curcumin phytosome) at a dosage of 1 g/day (two tablets/day) for four weeks
Study: 7696451
Drug: Low viscosity
Normalized name: Gentamicin low viscosity bone cement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low viscosity budesonide enema (2 mg/100 mL)
Study: 2821947
Drug: Higher dosages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dosages of enalapril (40 and, if necessary 60 mg once‐a‐day)
Study: 2821947
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg and hydrochlorothiazide 25 and, if necessary, 50 mg once‐a‐day
Study: 26096889
Drug: Intravenous diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diclofenac sodium 37.5 mg
Study: 26096889
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac potassium 50 mg
Study: 24438902
Drug: Dendritic cell
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendritic cell immunotherapy (6 doses intravenous over 14 weeks)
Study: 24438902
Drug: Dendritic cell
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendritic cell immunotherapy
Study: 18782484
Drug: Diet plus
Normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet plus protein-calorie supplementation (formula providing 250 kcal + 20 g protein)
Study: 12927639
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with pulsed ultrasound and interferential current (CTPI)
Study: 28019683
Drug: Teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide 20 μg QD
Study: 28019683
Drug: Risedronate 35
Normalized name: risedronate 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 35 mg QW
Study: 17168358
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (radical surgery plus pre- and intraoperative radiotherapy)
Study: 1565181
Drug: 24,25-dihydroxycholecalciferol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24,25-dihydroxycholecalciferol (10 micrograms daily for 3 months)
Study: 31858840
Drug: Photodynamic Therapy-ALA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic Therapy-ALA following fractional CO2 Laser
Study: 30485924
Drug: Probiotic Lactobacillus
Normalized name: Probiotic Lactobacillus Acidophilus Caplets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Lactobacillus casei Shirota (LcS) administered daily for 1 month
Study: 30485924
Drug: Placebo (skimmed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (skimmed milk without probiotic) administered daily for 1 month
Study: 26407124
Drug: pirfenidone tablets
Normalized name: Pirfenidone Tablets
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: pirfenidone tablets (0.4 g) with food
Study: 26407124
Drug: pirfenidone tablets
Normalized name: Pirfenidone Tablets
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: pirfenidone tablets (0.4 g) with grapefruit juice
Study: 17697908
Drug: Rupatadine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine 20 mg under fed conditions
Study: 16120152
Drug: Narrowband ultraviolet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrowband ultraviolet B monotherapy
Study: 10655708
Drug: Irradiation in
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irradiation in breast conservation therapy (BCT)
Study: 25452222
Drug: Guided mastery
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided mastery therapy
Study: 25660206
Drug: Hypnotic suggestion
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic suggestion
Study: 1676212
Drug: Topical salicylic
Normalized name: salicylic acid Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical salicylic acid
Study: 31843964
Drug: LPS infusion
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS infusion
Study: 26577263
Drug: Coronary CTA-guided
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coronary CTA-guided treatment strategy
Study: 21163569
Drug: Intravesical BCG
Normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical BCG (27 mg)
Study: 11339519
Drug: meloxicam 7.5
Normalized name: meloxicam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: meloxicam 7.5 mg tablet
Study: 11339519
Drug: diclofenac 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 100 mg slow release tablet
Study: 9217822
Drug: 0.1% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% tretinoin cream applied once a day for 1 week (n=10)
Study: 7811656
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg intranasal midazolam
Study: 9278798
Drug: rimexolone 1%
Normalized name: RIMEXOLONE 1% SUSP,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: rimexolone 1% ophthalmic suspension
Study: 8348392
Drug: Lovastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20 mg/day, increased to max 80 mg/day)
Study: 8348392
Drug: Simvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (10 mg/day, increased to max 40 mg/day)
Study: 3799503
Drug: Unsupplemented group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupplemented group (3-5 micrograms Se/L)
Study: 31570084
Drug: Low-dose tirofiban
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tirofiban treatment within the first 24 hours after IVT
Study: 26130744
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus carboplatin (10 mg/kg every 2 weeks and carboplatin AUC 5 every 4 weeks)
Study: 26130744
Drug: Bevacizumab monotherapy
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab monotherapy (10 mg/kg every 2 weeks)
Study: 11472243
Drug: Antitumor prodrug
Normalized name: Troxacitabine nucleotide prodrug miv-818
DrugBank: Fostroxacitabine bralpamide (DB18090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antitumor prodrug monotherapy targeting tumor-associated factors (hypoxia, enzymes, receptors)
Study: 9448149
Drug: Interferon-alpha (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha (3 million U three times weekly for 6 months)
Study: 7612090
Drug: Double phototherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double phototherapy (n = 19) with irradiance of 33 to 35 microW/cm2/nm in addition to single conventional phototherapy with combination of three or four special blue and white lamps with irradiance of 7 to 9 microW/cm2/nm
Study: 25740691
Drug: Balugrastim 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balugrastim 450 µg/kg
Study: 29573207
Drug: Pegfilgrastim 6
Normalized name: PEGFILGRASTIM 6MG/0.6ML DELIVERY KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim 6 mg
Study: 25740691
Drug: Balugrastim (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balugrastim (both doses)
Study: 7537664
Drug: Casodex 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex 150 mg/day
Study: 2739826
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine infusion (0.1 microgram/kg/min) + hydrosaline retention